Oak Ridge National Laboratory researchers have developed artificial intelligence software for powder bed 3D printers that assesses the quality of parts in real time, without the need for expensive characterization equipment.
Juergen Rapp, a distinguished R&D staff scientist in ORNL’s Fusion Energy Division in the Nuclear Science and Engineering Directorate, has been named a fellow of the American Nuclear Society
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
Oak Ridge National Laboratory researchers working on neutron imaging capabilities for nuclear materials have developed a process for seeing the inside of uranium particles – without cutting them open.
As scientists study approaches to best sustain a fusion reactor, a team led by Oak Ridge National Laboratory investigated injecting shattered argon pellets into a super-hot plasma, when needed, to protect the reactor’s interior wall from high-energy runaway electrons.
Researchers at the Department of Energy’s Oak Ridge National Laboratory have received five 2019 R&D 100 Awards, increasing the lab’s total to 221 since the award’s inception in 1963.
Using additive manufacturing, scientists experimenting with tungsten at Oak Ridge National Laboratory hope to unlock new potential of the high-performance heat-transferring material used to protect components from the plasma inside a fusion reactor. Fusion requires hydrogen isotopes to reach millions of degrees.
The Department of Energy’s Oak Ridge National Laboratory is collaborating with industry on six new projects focused on advancing commercial nuclear energy technologies that offer potential improvements to current nuclear reactors and move new reactor designs closer to deployment.
Scientists from Oak Ridge National Laboratory performed a corrosion test in a neutron radiation field to support the continued development of molten salt reactors.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.